Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

@article{Heller2012InsulinDA,
  title={Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial},
  author={Simon R. Heller and John B. Buse and Miles Fisher and Satish Kumar Garg and Michel Marre and Ludwig Merker and Eric Renard and David L. Russell-Jones and Areti Philotheou and A. M. Ocampo Francisco and Huiling Pei and Bruce W. Bode},
  journal={The Lancet},
  year={2012},
  volume={379},
  pages={1489-1497}
}

Figures and Tables from this paper

Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.

In this post hoc meta-analysis, more than 30% of subjects with T2D required >60 U/day of basal insulin at the end of the trials and IDeg achieves similar HbA1c reduction with significantly less overall and nocturnal confirmed hypoglycemia compared with IGlar.

Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials

Compared with glargine, degludec is associated with equivalent HbA1c control and significantly lower nocturnal hypoglycemia rates and is also associated with significantly greater reductions in FPG and lower total doses of insulin versus glargines in T1DMB/B and T2DMinsulin-naïve.

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

Insulins degludec and glargine administered once daily in combination with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with deglUDec.

Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study

IDeg yielded a lower FPG level and smaller day-to-day variability of FPG at a lower daily dose compared with IGlar in participants with type 1 diabetes, and serves as a good option for basal insulin in the treatment of type 2 diabetes.

Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study

DEG improved glycemic control when switched from once-daily BI and maintained gly glucose control when switch from twice- daily BI without increasing hypoglycemia.

Treating to target in type 2 diabetes: the BEGIN trial programme.

In clinical trials, insulin degludec achieved similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower risk of nocturnal hypoglycaemia.

Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.

It is suggested that short-term efficacy and safety of IDeg and IGla in patients with type 2 diabetes during the initial phase of basal-bolus therapy were comparable, and these results can help in deciding which treatment to opt for.
...

References

SHOWING 1-10 OF 28 REFERENCES

A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.

The data suggest that insulin glargine, in combination with insulin lispro, is safe and effective when administered before breakfast, before dinner, or at bedtime.

A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

In this clinical exploratory phase 2 trial in people with type 1 diabetes, IDeg is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile that provides comparableglycemic control toIGlaratsimilardoses, with reduced rates of hypoglycemia.

Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine

IDeg has a half-life that is twice as long as IGlar with a more evenly distributed and stable pharmacokinetic exposure and glucose-lowering effect, over 24 hours at steady state in patients with T1D.

Hypoglycemia rates with basal insulin analogs.

An overview of the hypoglycemic data available from the randomized controlled trials comparing insulin glargine and insulin detemir with NPH or continuous subcutaneous insulin infusion in type 1 and type 2 diabetes is presented.

Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes.

Treatment with IAsp is associated with an increase in cross-reactive insulin antibodies, with a subsequent fall toward baseline values, without any indication of clinical relevance, and there was no consistent relationship between antibody formation and glycemic control or between antibodies formation and safety in terms of adverse events.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus

Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.

The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control.

The CGMS is useful for detecting unrecognized hypoglycemias in type 1 and type 2 diabetic subjects; however, it is not better than standard capillary glucose measurements for improving metabolic control of type 1 diabetic subjects, regardless of the therapeutic regimen.

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes, and changes between treatment groups remained significant after adjusting for these factors.

Refining basal insulin therapy: what have we learned in the age of analogues?

The basal insulin analogues glargine and detemir have been subject to a series of trials comparing their clinical profiles to the conventional preparation, neutral protamine Hagedorn (NPH). Careful

Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61

The new standards set by the American Diabetes Association in 2011 recommend universal screening at 24–28 weeks of gestation and an oral glucose tolerance test with a diagnostic fasting plasma glucose of ≥92 mg/dL (4.5 mmol/L) (much lower than the World Health Organization criteria).